QUIMILZA3VI Trademark

Trademark Overview


On Wednesday, December 17, 2025, a trademark application was filed for QUIMILZA3VI with the United States Patent and Trademark Office. The USPTO has given the QUIMILZA3VI trademark a serial number of 99552608. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Wednesday, December 17, 2025. This trademark is owned by Vanda Pharmaceuticals Inc.. The QUIMILZA3VI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for treating epidermal problems; Pharmaceutical preparations for the treatment of generalized pustular psoriasis (GPP); Pharmaceutical preparations for the treatment of a disease or disorder that is responsive to IL-36R inhibition or neutralization, namely, a disease or disorder in which a decrease in IL-36R levels or activity has a therapeutic benefit; Pharmaceutical preparations for the treatment of a disease or disorder that is responsive to IL-36R inhibition or neutralization, namely, a disease or disorder in which the improper expression or increased activity of IL-36R causes or contributes to the pathological effects of the disease or disorder; Pharmaceutical preparations for the treatment of a disease or disorder that is responsive to IL-36R inhibition or neutralization, namely, inflammatory diseases, autoimmune diseases, respiratory diseases, metabolic disorders, and cancer; Pharmaceutical prep...
quimilza3vi

General Information


Serial Number99552608
Word MarkQUIMILZA3VI
Filing DateWednesday, December 17, 2025
Status630 - NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
Status DateWednesday, December 17, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for treating epidermal problems; Pharmaceutical preparations for the treatment of generalized pustular psoriasis (GPP); Pharmaceutical preparations for the treatment of a disease or disorder that is responsive to IL-36R inhibition or neutralization, namely, a disease or disorder in which a decrease in IL-36R levels or activity has a therapeutic benefit; Pharmaceutical preparations for the treatment of a disease or disorder that is responsive to IL-36R inhibition or neutralization, namely, a disease or disorder in which the improper expression or increased activity of IL-36R causes or contributes to the pathological effects of the disease or disorder; Pharmaceutical preparations for the treatment of a disease or disorder that is responsive to IL-36R inhibition or neutralization, namely, inflammatory diseases, autoimmune diseases, respiratory diseases, metabolic disorders, and cancer; Pharmaceutical preparations for the treatment of an inflammatory disorder, namely, allergic inflammation of the skin, lungs, and gastrointestinal tract, atopic dermatitis or atopic eczema, allergic asthma and non-allergic asthma, epithelial-mediated inflammation, fibrosis, idiopathic pulmonary fibrosis, scleroderma, kidney fibrosis, scarring, allergic rhinitis, food allergies, seasonal allergies, and other allergies; Pharmaceutical preparations for the treatment of an autoimmune disease, namely, multiple sclerosis, asthma, type 1 diabetes mellitus, rheumatoid arthritis, scleroderma, Crohn's disease, psoriasis vulgaris or psoriasis, pustular psoriasis, generalized pustular psoriasis (GPP), palmo-plantar pustulosis (PPP), inflammatory bowel disease, psoriatic arthritis, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus (SLE), ulcerative colitis, and ankylosing spondylitis; Pharmaceutical preparations for the treatment of a respiratory disease, namely, asthma, cystic fibrosis, emphysema, chronic obstructive pulmonary disease (COPD), and acute respiratory distress syndrome; Pharmaceutical preparations for the treatment of a metabolic disorder, namely, obesity, type 2 diabetes, atherosclerosis, and cardiovascular disease; Pharmaceutical preparations for the treatment of cancer, namely, melanoma, renal cell carcinoma, lung cancer, bladder cancer, breast cancer, cervical cancer, colon cancer, gall bladder cancer, laryngeal cancer, liver cancer, thyroid cancer, stomach cancer, salivary gland cancer, prostate cancer, pancreatic cancer, leukemia, lymphoma, and Merkel cell carcinoma; Pharmaceutical preparations for the treatment of a chronic skin condition, namely, hidradenitis suppurativa; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, December 17, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameVanda Pharmaceuticals Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWashington, DC 20037

Trademark Events


Event DateEvent Description
Wednesday, December 17, 2025NEW APPLICATION ENTERED
Wednesday, December 17, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, December 17, 2025APPLICATION FILING RECEIPT MAILED